| 2.35 -0.15 (-6%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.06  |
1-year : | 3.29 |
| Resists | First : | 2.62 |
Second : | 2.81 |
| Pivot price | 2.59 |
|||
| Supports | First : | 2.3 |
Second : | 1.91 |
| MAs | MA(5) : | 2.59 |
MA(20) : | 2.59 |
| MA(100) : | 3.3 |
MA(250) : | 5.65 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.2 |
D(3) : | 53.4 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 13.98 | Low : | 2.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVXL ] has closed below the lower bollinger band by 9.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ AVXL ] is to continue within current trading range. It is unclear right now based on current values. 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.51 - 2.52 | 2.52 - 2.54 |
| Low: | 2.27 - 2.29 | 2.29 - 2.3 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Fri, 22 May 2026
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification - Anavex Life Sciences
Sun, 26 Apr 2026
What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks - Yahoo Finance
Tue, 07 Apr 2026
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference - Anavex Life Sciences
Thu, 26 Mar 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL - PR Newswire
Wed, 25 Mar 2026
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - Anavex Life Sciences
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 43.9 (%) |
| Shares Short | 14,230 (K) |
| Shares Short P.Month | 18,830 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.6 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -5.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|